In the majority of AML cases, they identified both a CD34+CD38−CD90−CD45RA+ population resembling lymphoid-primed multipotent progenitors (LMPP-like LSCs) and a more differentiated CD34+CD38+CD123+/lowCD110−CD45RA+ population resembling granulocyte-monocyte progenitors (GMP-like LSCs). Here, CD34 is linked to acute myeloid leukemia.